home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Alkermes

SHARESHARESHARE
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information.
SHARESHARESHARE

RELATED NEWS


The US Food and Drug Administration (FDA) has approved Biogen and Alkermes’ oral drug Vumerity (diroximel fumarate) to treat relapsing forms of multiple sclerosis (MS). Biogen holds the exclusive licence to commercialise the drug globally and intends to make it available in the US in the coming days. Biogen chief medical officer and research and development executive vice-president Alfred Sandrock said: “The FDA’s approval of Vumerity delivers on Biogen’s commitment to pu...

READ MORE

Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA turned down its marketing application. The negative outcome for the review isn’t surprising given that an FDA advisory committee voted by 21-2 in November that the drug’s benefit-risk profile is not adequate to support its approval for treatment-resistant MDD. However, the outcome is something of a worst-case scenario for Alkermes as it seems the US regulator wants a new cli...

READ MORE

Alkermes' schizophrenia drug met its primary endpoints in a second phase 3 trial, setting it up for an FDA filing in mid-2019. Patients taking the drug gained less weight on average than patients taking olanzapine, the antipsychotic on which it is based. Olanzapine is one of the most commonly prescribed treatments for schizophrenia, but can cause a number of side effects, including metabolic issues and extreme weight gain. Because of this, Eli Lilly, which markets olanzapine as Zyprexa, had ...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...